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Abstract 
 The endothelium produces and responds to reactive oxygen and nitrogen species 
(RONS), providing important redox regulation to the cardiovascular system in physiology and 
disease. In no other situation are RONS more critical than in the response to tissue ischemia. 
Here, tissue healing requires growth factor-mediated angiogenesis that is in part dependent on 
low levels of RONS, which paradoxically must overcome the damaging effects of high levels of 
RONS generated as a result of ischemia. While generation of endothelial cell RONS in 
hypoxia/reoxygenation is acknowledged, the mechanism for their role in angiogenesis is still 
poorly understood. During ischemia, the major low molecular weight thiol glutathione (GSH) 
reacts with RONS and protein cysteines, producing GSH-protein adducts. Recent data indicate 
that GSH adducts on certain proteins are essential to growth factor responses in endothelial 
cells. Genetic deletion of the enzyme glutaredoxin-1, which selectively removes GSH protein 
adducts, improves, while its overexpression impairs, revascularization of the ischemic hindlimb 
of mice. Ischemia-induced GSH adducts on specific cysteine residues of several proteins, 
including p65 NFkB and the sarcoplasmic reticulum calcium ATPase (SERCA2), appear to 
promote ischemic angiogenesis. Identifying the specific proteins in the redox response to 
ischemia has provided therapeutic opportunities to improve clinical outcomes of ischemia. 
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Introduction 
 Reactive oxygen, eg. superoxide anion and hydrogen peroxide, and reactive nitrogen 
species, eg. nitric oxide and peroxynitrite, (RONS) are low molecular weight reactive species 
created as a result of metabolism in respiring cells. Elevated levels of RONS have been 
measured in countless studies of various cardiovascular and metabolic diseases, notably 
diabetes mellitus, and in animal models, scavenging of the oxidants has therapeutic benefits. 
When they are present at high levels or for prolonged times, one of the most prevalent reasons 
for the adverse effects of RONS is the irreversible damage to proteins, requiring protein 
degradation and re-synthesis to return protein function. Such damage is evidenced by 
biologically irreversible post-translational chemical modifications. Although many such 
modifications have been identified, the one with most notoriety is nitrotyrosine1 due to the early 
development of a specific antibody. Nitrotyrosine, and other irreversible oxidative post-
translational modifications (OPTM), chlorotyrosine, methionine sulfoxide, and cysteine sulfonic 
acid (-SO3H), are all recognized biomarkers of oxidant stress  occurring in animal models and 
found in tissue and blood of human patients with cardiovascular disease2,3,4,5,6. These 
biomarkers have been demonstrated on proteins whose functions are essential to cellular 
homeostasis, including albumin7, endothelial nitric oxide synthase (eNOS)8, prostacyclin 
synthase9, the sarcoplasmic-endoplasmic reticulum calcium ATPase (SERCA)10,11 , 
manganese superoxide dismutase12, and p21Ras13. As an example, nitrotyrosine-modified 
proteins accumulate in endothelial cells of skeletal muscle in a commonly used mouse model 
of hindlimb ischemia
14,15
. In this model, a one centimeter length of the femoral artery is ligated 
and excised, allowing serial measurements of blood flow and other parameters over several 
weeks, during which angiogenesis and revascularization return blood flow to near normal. As 
another example of irreversible protein oxidation within endothelial cells during hindlimb 
ischemia in the mouse, the reactive cysteine-674 thiol of SERCA2 is in part irreversibly 
oxidized to the sulfonic acid as revealed by a specific antibody (Figure 1).  
 
Signaling in endothelial cells by thiol adducts 
 Lower levels of RONS are now recognized to be essential for cell signaling functions. 
For example, there is substantial evidence that nitric oxide (NO) is an endogenous mediator of 
growth factor-mediated angiogenesis16, and in therapeutic amounts, NO can provide 
substantial protection from the effects of ischemia17. Also, interference with normal functions of 
low-level RONS is a potential reason why application of non-specific scavenging antioxidants 
such as vitamin C and E have failed as therapies for diseases involving damage caused by 
high levels of RONS. These factors suggest that mammalian cells have developed 
mechanisms to utilize low levels of RONS, while protecting themselves from higher levels. 
While not exclusively so, the major signaling actions of RONS are mediated by reversible 
protein modifications on cysteine residues18,19,20. Alterations in function are associated with 
multiple oxidative modifications of the thiol group (Figure 2). The primary targets include 
cysteines that are accessible on the protein surface, as well as those that are maintained in the 
chemically reactive thiolate anion state (-S- rather than -SH) by nearby positively charged 
arginine and lysine amino acids. Although high concentrations of RONS widely oxidize 
cysteines and other amino acids on proteins, low levels of RONS affect these reactive 
cysteines more specifically. As an example, during growth factor initiated signaling in 
endothelial cells, the thiol of cysteine-674 of SERCA2 serves as the exclusive target for 
glutathione (GSH) adducts. Despite the fact that there are many other cysteine thiols on the 
exterior of the protein, a cysteine to serine mutation of this one thiol nearly eliminates all GSH 
adducts occurring on the protein during growth factor-induced angiogenesis21. NO is well 
documented to produce S-nitroso thiols (-SNO), and hydrogen peroxide to produce sulfenic 
acid (-SOH) modification of thiols22,23. However, both of these thiol modifications readily react 
with abundant intracellular GSH to form the more stable GSH adduct (-SSG). In response to 
direct challenge with various oxidants in vitro, or in particular in response to ischemia in vivo, 
large amounts of glutathione adducts appear on reactive cysteines. As an example, during the 
first 24 hours of ischemia, cysteine-674 of SERCA2 abundantly forms GSH adducts that 
persist for at least several days (Figure 3).  
 
Glutaredoxin-1 
 Likely because of the chemical stability of GSH cysteine adducts, the cell has evolved 
several thiol reductase enzymes that can remove GSH adducts. While thioredoxins and 
peroxidoxins are abundant thiol reductases, glutaredoxin-1 (Glrx1) is the most selective in its 
ability to remove GSH protein adducts3. This 12 kiloDalton protein removes GSH adducts from 
a protein cysteine thiol by transferring the GSH adduct to one of its own reactive thiols on 
cysteine 23 or 26. Glrx1 is then reduced by free GSH, completing the catalytic cycle (Figure 4). 
There is growing awareness of the importance of Glrx1 as a physiological regulator 24–34. Our 
studies show that Glrx1 regulates hindlimb ischemia, when the abundance of GSH adducts is 
high. The level of protein GSH adducts present in ischemic muscle and the restoration of blood 
flow during the two weeks following femoral artery excision was significantly enhanced in 
global Grx1 knockout mice35, consistent with an essential role of GSH adducts in the response 
to ischemia. In contrast, GSH adducts in the ischemic muscle were decreased and restoration 
of blood flow was impaired in global Glrx1 overexpressing transgenic mice (Figure 5)28. 
Additionally, when compared to wild type mice, endothelial-specific overexpression of Glrx1 
impaired the recovery from ischemia, resulting in necrotic loss of toes35., Together, these 
findings indicate a critical role for GSH adducts on endothelial cell proteins during the response 
to ischemia. Furthermore, these studies establish Grx1 as a critical regulator and potential 
therapeutic target to address in improving clinical outcomes of limb ischemia. 
 
Redox regulation of cellular mechanisms of angiogenesis in endothelial cells 
 During a normal response to ischemia induced by femoral artery excision, the 
involvement of RONS is well established. Throughout the subsequent recovery of blood flow, 
collateral arteries grow in diameter to conduct blood flow around the blocked artery, and the 
numbers of capillaries increase within ischemic muscle tissue. The increase in number of 
capillaries, termed angiogenesis, requires endothelial cell proliferation and migration driven by 
increased production by the ischemic cells of growth factors, the most abundant of which is 
vascular endothelium growth factor (VEGF). In cultured endothelial cells, VEGF causes 
proliferation, migration, and capillary-like tube formation. These endothelial angiogenic 
responses require signaling elements that mediate the response to VEGF including VEGF 
receptor-2, phosphatidylinositol-3 kinase, Akt phosphorylation, endothelial nitric oxide synthase 
(eNOS) phosphorylation, and NO production. NO and eNOS have proven to be essential in the 
angiogenic response in vivo, as demonstrated by the fact that the eNOS knockout mouse has 
only minimal restoration of blood flow following femoral artery ligation16. The activation of 
angiogenic behavior in cultured endothelial cells by VEGF can be mimicked by direct addition 
of micromolar concentrations of exogenous NO21.  
Interestingly, NO does not work alone, but requires other RONS. First, intracellular 
superoxide anion is required, as demonstrated by the fact that overexpression of either 
superoxide dismutase 1 or 2 prevents both VEGF and NO-induced endothelial cell migration36. 
Superoxide anion is also required in vivo for the restoration of hindlimb blood flow in ischemia 
as indicated by a subnormal return of blood flow in mice deficient in Nox2 (gp91phox), a 
component of NADPH oxidase,37 a major source of superoxide anion. The actual chemical 
identity of the essential RONS for a normal endothelial response to VEGF is uncertain. It has 
been suggested that peroxynitrite (ONOO-), the reaction product of nitric oxide and superoxide,  
is the true signaling RONS based on inhibition of VEGF-induced angiogenic responses by a 
ONOO
-
 degradation catalyst38. This also makes sense from the point of view that ONOO- is a 
much more potent thiol oxidant. For example, low micromolar concentrations of ONOO- induce 
protein GSH adducts in cell free systems on cysteine-674, the reactive thiol on SERCA2, much 
more effectively than do similar concentrations of nitric oxide alone39.  
NO and superoxide are not the only RONS required for angiogenesis, because 
scavenging of hydrogen peroxide (H2O2) by overexpression of catalase inhibits hindlimb 
ischemia-induced angiogenesis in vivo40 and angiogenic endothelial cell responses to VEGF in 
culture
36,39
. Indeed, low micromolar concentrations of H2O2 induce cell migration that mimics 
the  response to VEGF36. NADPH oxidase (Nox) 4 apparently provides the H2O2, as 
knockdown of its expression globally41 or selectively in endothelial cells42 in vivo inhibits the 
angiogenic response to ischemia and prevents the angiogenic responses to VEGF in cell 
culture. The interaction of NO, superoxide anion, and H2O2 is complex, but we found that H2O2 
production by Nox4 is upstream of superoxide anion production by Nox236. Namely, the 
angiogenic response to exogenous H2O2 or VEGF is prevented by overexpression of 
intracellular superoxide dismutase (directly removing the downstream mediator, superoxide) as 
well as knockdown of Nox2 (the producer of superoxide)36. Thus, both H2O2 from Nox4 and 
superoxide anion from Nox2 appear to be required for NO to perform its angiogenic functions.  
The requirements for nitric oxide, Nox4-derived H2O2, and Nox2-derived superoxide 
anion to achieve a normal angiogenic response to VEGF also extend to the ability of the 
growth factor to stimulate protein GSH adducts in endothelial cells in culture36. This is also 
compatible with the previously noted suggestion that ONOO- is essential for protein GSH 
adducts to form in sufficient abundance for VEGF signaling. Indeed, like the scavengers of 
RONS mentioned above, overexpression of Glrx1 prevents formation of GSH protein adducts 
and completely prevents VEGF-induced angiogenic responses in cultured endothelial cells21.  
 
Involvement of GSH adducts on specific proteins in the redox regulation of 
angiogenesis 
 It is clear from proteomics studies of endothelial cell proteins on which GSH adducts 
form during ischemia, that multiple, perhaps hundreds of, proteins are involved35,43. This is as 
might be expected, given that ischemia results in high concentrations of RONS and hundreds 
of proteins have been identified to have reactive cysteines 44. While it is uncertain if and how 
all the proteins on which GSH adducts occur are involved in the angiogenic response, it is 
certain that several are essential.  
 GSH adducts on the cysteine-674 thiol of SERCA2 are one example of a 
mechanistically essential GSH adduct. First, GSH adducts form abundantly on the SERCA2 
thiol during the first 3 days of ischemia (Figure 3). The importance of this cysteine was 
demonstrated in a heterozygote mouse in which one allele of SERCA2 was mutated to encode 
a serine in place of cysteine-67445. Total GSH adducts on SERCA2 in ischemic muscle were 
decreased approximately 50%, consistent with this single thiol being the primary site for GSH 
adduct formation on SERCA2 
21,39
. In cultured endothelial cells, knockdown of SERCA2 
expression prevented VEGF-induced calcium influx, cell migration, and capillary-like network 
formation. The importance of SERCA2 was attributed to its role in refilling intracellular calcium 
stores, which, in turn, regulates entry of the extracellular calcium required for angiogenic 
responses to VEGF. Overexpression of a SERCA2 cysteine-674 serine mutant or 
overexpression of Glrx1 in endothelial cells largely prevented increases in GSH adducts on 
SERCA2, calcium signaling, and angiogenic responses to VEGF. In addition, the mouse in 
which 50% of the redox-sensitive cysteines were mutated to serine showed impaired 
restoration of blood flow in the ischemic hindlimb (Figure 3). The fundamental importance of 
GSH adducts on cysteine-674 of SERCA2 for growth factor-mediated angiogenesis was also 
evidenced by the fact that the mouse with homozygote substitution of the SERCA2 serine 
mutation died in utero at the stage when heart and vascular development occur45.  
 GSH protein adducts on any of several components involved in NFkB signaling inhibits 
activation of the pathway, i.e. by inactivating IKK25 and limiting the DNA binding ability of p6546 
and p50
47
. For example, increased GSH adducts were noted on p65 in normal ischemic 
hindlimb muscle and endothelial cells exposed to hypoxia, suggesting that during ischemia, 
NFkB activity is inhibited by glutathione adduct formation (Figure 5). On the contrary, NFkB 
activity is dramatically increased in endothelial cells cultured from transgenic mice 
overexpressing Glrx128. Overexpression of Glrx1 in endothelial cells prevented p65 GSH 
adducts and resulted in the activation of NFkB. A consequence of this activation was increased 
production of the non-canonical Wnt ligand, Wnt5a, levels of which rose dramatically in the 
ischemic hindlimbs of Glrx1 transgenic mice. Wnt5a, in turn, increased production of soluble 
Flt, an alternatively spliced VEGF receptor that acts as a decoy, interfering with binding and 
response to VEGF28. Knocking down the expression of sFlt restored angiogenic function to 
endothelial cells that overexpressed Glrx1
28
. Regulation and downstream targets of NF-kB are, 
however, complex. However, mice with dominant negative IκBα, in which NF-kB is inhibited, 
showed decreased blood flow recovery after hindlimb ischemia48. Induction of sFlt in Glrx1 
overexpressing mice may result not only from NF-kB activation but also other transcriptional 
controls regulated by GSH adducts.  
 Phosphatases (eg. protein tyrosine phosphatase-1B and protein phosphatase-2A) are 
protein targets that are inhibited by oxidants, resulting in increased phosphorylation and 
activation of kinase signaling. VEGF was shown to induce increases in GSH adducts on low 
molecular weight protein tyrosine phosphatases49. In cultured endothelial cells, inhibition of the 
phosphatases by GSH adducts was required for increases in tyrosine phosphorylation and 
increased activity of focal adhesion kinase, a key mediator of endothelial cell migration. Either 
antioxidants or a ONOO
- decomposition catalyst were able to prevent GSH adducts from 
forming on the phosphatase, and thus prevented kinase activation. These studies indicate that 
endothelial cell migration requires GSH adducts and inhibition of the phosphatase to allow 
downstream kinase signaling. 
p21ras is essential for angiogenesis. Glutathione adducts on cysteine 118 of p21ras 
substantially increase its activity50, so it is possible that this small GTPase is another key 
protein that is redox-regulated by GSH adducts during ischemic angiogenesis. It is known that 
mutation of cysteine-118 in p21ras prevents a critical angiogenic role of eNOS in tumor 
maintenance 
51, making it likely that GSH adducts are involved. 
Whereas GSH adducts on the above cited proteins would appear to aid in the 
restoration of blood flow during ischemia, GSH adducts on some proteins known to be 
essential in the angiogenic response to ischemia may have adverse consequences. For 
example, both eNOS16 and sirtuin-152 are essential to normal angiogenesis and possess 
reactive cysteines that when adducted with GSH affect their function. However, GSH adducts 
on both eNOS
32
 and sirtuin-153 inhibit their catalytic activities, which would therefore be 
predicted to have a deleterious effect on ischemia-induced angiogenesis.  As GSH adducts on 
both proteins are reduced by Grx154,32, the deleterious effect of Grx1 itself cannot be 
explained. This apparent contradiction could exist for several reasons, including the possibility 
that these proteins are protected from GSH adducts during ischemia because of subcellular 
localization (eg. calveoli and nucleus, respectively), or that the global effects of up- or down-
regulation of Grx1 expression overrides changes in the function of these two proteins. It is also 
possible that because GSH adducts on eNOS uncouple the enzyme32, the increased ONOO- 
that results may benefit VEGF signaling by further increasing GSH adducts.  
  
Summary and future directions 
It is now evident that GSH adducts form abundantly on proteins during ischemia, and 
that from studies of up- and down-regulation of Grx1, formation of these adducts is important 
to the outcome of ischemia. It is possible that the benefit of GSH adducts on many proteins 
during ischemia is derived from protecting critical reactive cysteines against potential 
irreversible oxidation.The resulting preservation of cysteine function could explain the adverse 
consequences of overexpression and the benefit of knockdown of Grx1. This then suggests 
that inhibition of Grx1, because of its generalized effects on GSH adducts during ischemia, 
might be one therapeutic maneuver identified by these studies. It is also possible to affect GSH 
adduct formation by influencing GSH levels and the redox state of GSH itself, which is 
regulated by GSH reductase and GSH synthase, amongst other factors. 
The global increase in GSH adducts during ischemia is difficult to reconcile with the 
apparent importance of the redox state of reactive cysteines in the function of individual 
proteins. The evidence, for instance, that GSH adducts on one cysteine of SERCA are 
essential to angiogenic growth factor signaling and that a 50% substitution of the cysteine 
inhibits ischemic angiogenesis in vivo, suggests that GSH adducts on some proteins might be 
more important than on others. If this is so, it might be possible to use the redox state of these 
particular cysteines, such as was measured for SERCA cysteine-674 with 
immunohistochemistry in Figure 1, as an indicator or biomarker of a favorable or unfavorable 
response to ischemia. Potentially, proteins have evolved with reactive cysteines, in part, for 
protection from ischemia, or other acute adverse redox conditions. This notion is supported by 
preliminary proteomic studies that we designed to identify which endothelial cell proteins have 
GSH adducts on reactive cysteines. Using systems biology approaches, these studies show 
that many proteins in several categories of tissue healing and angiogenesis have increased 
adducts during prolonged hypoxia, raising the possibility that protection of these categories of 
proteins in particular has evolved to improve the response to adverse oxidative stress 
conditions including ischemia. Future systems biology analysis might reveal that proteins with 
essential reactive cysteines work not alone, but in unison to accomplish a normal response  to 
ischemia. 
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Figure legends: 
1. Immuno-histochemical staining of oxidation of SERCA cysteine-674 in mouse hindlimb after 
3 weeks of ischemia. An antibody was produced against the irreversibly oxidized sulfonic 
acid in the SERCA2 sequence containing cysteine-674 and validated previously55. Marked 
increase in staining is present in endothelial cells of capillaries within the chronically 
ischemic muscle compared to a sham-operated limb and represents accumulation of the 
oxidized protein thiol during ischemia. Magnification 10x. 
2. Schematic representation of oxidative modifications of protein cysteine thiols. The reactive 
thiolate anion exposed to RONS forms reversible intermediates, -SNO and –SOH. These 
can be further oxidized to irreversible forms, sulfinic (-SO2H) and sulfonic (-SO3H) acids, or 
may react with free GSH to form GSH adducts. These adducts may be reversed by 
glutaredoxin-1 (Glrx1), forming oxidized GSH (GSSG) in the process.  
3. GSH adducts on SERCA2 cysteine-674 affect the severity of mouse hindlimb ischemia. A. 
Western blots with a monoclonal antibody against GSH protein adducts of immuno-
precipitated SERCA2 show increased adducts in ischemic (I) muscle compared to the non-
ischemic (N) muscle of wildtype (WT) mice 3 days following induction of ischemia. By 
comparison, there are decreased adducts in the ischemic limbs of a mouse expressing a 
heterozygote knockin allele (SKI) expressing a SERCA2 serine-674. Results of studies like 
those in panel A are summarized in panel B. C. LASER Döppler image of the ischemic limbs 
of WT and SKI mice after 28 days of ischemia. The ischemic limb is shown on the right; non-
ischemic on the left. D. LASER Döppler images obtained before (pre) and immediately post 
femoral artery excision, and following 7-28 days of recovery. Significantly impaired blood 
flow recovery was demonstrated at 21 and 28 days. Data from 45!"
4. Schematic diagram showing the molecular structure and catalytic activity of glutaredoxin-1. 
The 10 kDa protein has a CXXC motif containing cysteines 23 and 26 shown at left. The 
"
scheme at right shows how the chemically reduced Glrx1 (two –SH groups) reacts with a 
protein GSH adduct, reducing the protein thiol in the process and taking on the GSH adduct. 
The oxidized glutaredoxin-1 then reacts with GSH to form GSSG, returning glutaredoxin-1 to 
the fully reduced form.  
5. Glutaredoxin-1 overexpression impairs hindlimb ischemia. A. LASER Döppler and 
photographic images of ischemic (right) hind limbs of WT mice and transgenic mice globally 
overexpressing glutaredoxin-1 (TG). A marked lack of blood flow and cyanosis is seen in the 
transgenic mouse. Results of measurements made over 14 days of recovery are shown in 
panel B and indicate the worsened prolonged ischemia associated with glutaredoxin-1 
overexpression. Panel C summarizes results of studies to quantify reversible thiol oxidation 
of p65 NFkB in hindlimb muscle from WT and TG mice. Free protein thiols in muscle lysates 
were chemically blocked, and then reversibly oxidized thiols were reduced and labeled with 
a biotin containing thiol tag. Pull-down of biotin-labeled proteins on streptavidin was followed 
by gel electrophoresis and immuno-blotting for p65. Ischemia caused a 7-fold increase in 
reversible thiol oxidation on p65 in muscle from WT mice, but no significant increase in TG 
mice overexpressing glutaredoxin-1. The presumption being made is that glutaredoxin-1 
reduced GSH adducts on p65 thiols despite ischemic conditions. Panel D shows increased 
plasma levels of sFlt in TG mice at 4 and 14 days post-ischemia. Cell studies showed that 
sFlt, an antagonist of endothelial VEGF receptor-mediated signaling and angiogenic 
behavior, is normally suppressed during ischemia by GSH adducts on p65 that inhibit NFkB 
activity and Wnt5A-mediated sFlt production. In glutaredoxin-1 TG mice, fewer GSH adducts 
formed, and NFkB-dependent Wnt5A-mediated sFlt increased to explain impaired 
angiogenesis. From reference28. 
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